These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 7047168)

  • 1. Impaired effect of sulfonylurea following increased dosage.
    Wåhlin-Boll E; Sartor G; Melander A; Scherstén B
    Eur J Clin Pharmacol; 1982; 22(1):21-5. PubMed ID: 7047168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of sulfonylureas on the secretion, disposal and effect of insulin.
    Almér LO; Johansson E; Melander A; Wåhlin-Boll E
    Eur J Clin Pharmacol; 1982; 22(1):27-32. PubMed ID: 7047169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glyburide and glipizide, second-generation oral sulfonylurea hypoglycemic agents.
    Prendergast BD
    Clin Pharm; 1984; 3(5):473-85. PubMed ID: 6435940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetics-effect relations of glipizide and other sulfonylureas.
    Sartor G; Melander A; Scherstén B; Wåhlin-Boll E
    Acta Endocrinol Suppl (Copenh); 1980; 239():3-5. PubMed ID: 6776762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of sulfonylurea on the secretion and disposition of insulin and C-peptide.
    Almér LO; Johansson E; Melander A; Wåhlin-Boll E
    Acta Med Scand Suppl; 1981; 656():11-8. PubMed ID: 7046346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sulfonylurea treatment of insulin-independent diabetes mellitus.
    Feinglos MN; Lebovitz HE
    Metabolism; 1980 May; 29(5):488-94. PubMed ID: 6990184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evaluation of a new sulfonylurea in maturity onset diabetes - glipizide (K-4024).
    Bandisode MS; Boshell BR
    Horm Metab Res; 1976 Mar; 8(2):89-91. PubMed ID: 770300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glyburide and glipizide in treatment of diabetic patients with secondary failures to tolazamide or chlorpropamide.
    Lev JD; Zeidler A; Kumar D
    Diabetes Care; 1987; 10(6):679-82. PubMed ID: 3123183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diurnal pattern of plasma insulin and blood glucose during glibenclamide and glipizide therapy in elderly diabetics.
    Groop L; Harno K
    Acta Endocrinol Suppl (Copenh); 1980; 239():44-52. PubMed ID: 6776763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of sulfonylurea treatment on in vivo insulin secretion and action in patients with non-insulin-dependent diabetes mellitus.
    Greenfield MS; Doberne L; Rosenthal M; Schulz B; Widstrom A; Reaven GM
    Diabetes; 1982 Apr; 31(4 Pt 1):307-12. PubMed ID: 6759246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sulfonylureas enhance in vivo the effectiveness of insulin in type 1 (insulin dependent) diabetes mellitus.
    Pontiroli AE; Alberetto M; Bertoletti A; Baio G; Pozza G
    Horm Metab Res; 1984 Dec; 16 Suppl 1():167-70. PubMed ID: 6398258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacology of glipizide.
    Melander A; Wåhlin-Boll E
    Am J Med; 1983 Nov; 75(5B):41-5. PubMed ID: 6424440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma levels of glucose and lactate after intravenous glipizide administration in some insulin-dependent diabetics. Therapeutic effects of an associated glipizide-insulin treatment.
    Giampietro O; Navalesi R; Buzzigoli G; Boni C
    Curr Med Res Opin; 1979; 6(5):325-30. PubMed ID: 396109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic equivalence of once- and thrice-daily glipizide.
    Wåhlin-Boll E; Groop L; Karhumaa S; Groop PH; Tötterman KJ; Melander A
    Eur J Clin Pharmacol; 1986; 31(1):95-9. PubMed ID: 3536529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circadian variations of carbohydrate tolerance in maturity onset diabetics treated with sulfonylureas.
    Göschke H; Denes A; Girard J; Collard F; Berger W
    Horm Metab Res; 1974 Sep; 6(5):386-91. PubMed ID: 4417576
    [No Abstract]   [Full Text] [Related]  

  • 16. Bioavailability, pharmacokinetics and effects of glipizide in type 2 diabetics.
    Wåhlin-Boll E; Almér LO; Melander A
    Clin Pharmacokinet; 1982; 7(4):363-72. PubMed ID: 7116738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An open comparative study of the efficacy and tolerance of a new antidiabetic agent: glipizide.
    De Leeuw I; De Baere H; Decraene P; Lemmens P; Verhaegen H
    Diabetologia; 1973 Sep; ():364-6. PubMed ID: 4204093
    [No Abstract]   [Full Text] [Related]  

  • 18. Modifications of glycemia and insulinemia in diabetics treated with glipizide (K 4024), a new sulfonylurea.
    Fedele D; Tiengo A; Riva F; Muggeo M; Emanueli A; Crepaldi G
    Arzneimittelforschung; 1972 Nov; 22(11):1885-8. PubMed ID: 4679060
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparative single-dose kinetics and effects of four sulfonylureas in healthy volunteers.
    Sartor G; Melander A; Scherstén B; Wåhlin-Boll E
    Acta Med Scand; 1980; 208(4):301-7. PubMed ID: 6778079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and metabolic effects of glibenclamide and glipizide in type 2 diabetics.
    Groop L; Wåhlin-Boll E; Groop PH; Tötterman KJ; Melander A; Tolppanen EM; Fyhrqvist F
    Eur J Clin Pharmacol; 1985; 28(6):697-704. PubMed ID: 3933984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.